The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity
Open accessAbstract
Human Fas ligand (L) (CD95L) and tumor necrosis factor (TNF)-α undergo metalloproteinase-mediated proteolytic processing in their extracellular domains resulting in the release of soluble trimeric ligands (soluble [s]FasL, sTNF-α) which, in the case of sFasL, is thought to be implicated in diseases such as hepatitis and AIDS. Here we show that the processing of sFasL occurs between Ser126 and Leu127. The apoptotic-inducing capacity of naturally processed sFasL was reduced by >1,000-fold compared with membrane-bound FasL, and injection of high doses of recombinant sFasL in mice did not induce liver failure. However, soluble FasL retained its capacity to interact with Fas, and restoration of its cytotoxic activity was achieved both in vitro and in vivo with the addition of cross-linking antibodies. Similarly, the marginal apoptotic activity of recombinant soluble TNF-related apoptosis-inducing ligand (sTRAIL), another member of the TNF ligand family, was greatly increased upon cross-linking. These results indicate that the mere trimerization of the Fas and TRAIL receptors may not be sufficient to trigger death signals. Thus, the observation that sFasL is less cytotoxic than membrane-bound FasL may explain why in certain types of cancer, systemic tissue damage is not detected, even though the levels of circulating sFasL are high.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsudaira, P. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)61070-1 · Cited by 4,950
Nagata, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81874-7 · Cited by 4,938
Nagata, S., & Golstein, P. (1995) · Science · doi:10.1126/science.7533326 · Cited by 3,979
Phase separation of integral membrane proteins in Triton X-114 solution.
Bordier, C. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69848-0 · Cited by 3,324
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149
Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81266-0 · Cited by 3,046
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Chinnaiyan, A. M., O'Rourke, K., Tewari, M., & Dixit, V. M. (1995) · Cell · doi:10.1016/0092-8674(95)90071-3 · Cited by 2,431
Nicholson, D. W., & Thornberry, N. A. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(97)01085-2 · Cited by 2,409
Boldin, M. P., Goncharov, T. M., Goltseve, Y. V., & Wallach, D. (1996) · Cell · doi:10.1016/s0092-8674(00)81265-9 · Cited by 2,292
Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., & Peter, M. E. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00245.x · Cited by 2,184
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 2,005
Lethal effect of the anti-Fas antibody in mice
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., & Nagata, S. (1993) · Nature · doi:10.1038/364806a0 · Cited by 1,881
Monoclonal Antibody-Mediated Tumor Regression by Induction of Apoptosis
Trauth, B. C., Klas, C., Peters, A. M. J., Matzku, S., Möller, P., Falk, W., Debatin, K.-M., & Krammer, P. H. (1989) · Science · doi:10.1126/science.2787530 · Cited by 1,716
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., et al. (1997) · Science · doi:10.1126/science.277.5327.818 · Cited by 1,664
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)
Dhein, J., Walczak, H., Bäumler, C., Debatin, K.-M., & Krammer, P. H. (1995) · Nature · doi:10.1038/373438a0 · Cited by 1,609
Fas and Perforin Pathways as Major Mechanisms of T Cell-Mediated Cytotoxicity
Kägi, D., Vignaux, F., Ledermann, B., Bürki, K., Depraetere, V., Nagata, S., Hengartner, H., & Golstein, P. (1994) · Science · doi:10.1126/science.7518614 · Cited by 1,516
An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL
Pan, G., Ni, J., Wei, Y.-F., Yu, G.-L., Gentz, R., & Dixit, V. M. (1997) · Science · doi:10.1126/science.277.5327.815 · Cited by 1,496
Grell, M., Douni, E., Wajant, H., Löhden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., Lesslauer, W., Kollias, G., Pfizenmaier, K., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90192-2 · Cited by 1,325
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors
Thome, M., Schneider, P., Hofmann, K., Fickenscher, H., Meinl, E., Neipel, F., Mattmann, C., Burns, K., Bodmer, J.-L., Schröter, M., et al. (1997) · Nature · doi:10.1038/386517a0 · Cited by 1,315
Self-citationMelanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., et al. (1996) · Science · doi:10.1126/science.274.5291.1363 · Cited by 1,249
Self-citationProcessing of tumour necrosis factor-α precursor by metalloproteinases
Gearing, A. J. H., Beckett, P., Christodoulou, M., Churchill, M., Clements, J., Davidson, A. H., Drummond, A. H., Galloway, W. A., Gilbert, R., Gordon, J. L., et al. (1994) · Nature · doi:10.1038/370555a0 · Cited by 1,194
A role for CD95 ligand in preventing graft rejection
Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., & Duke, R. C. (1995) · Nature · doi:10.1038/377630a0 · Cited by 1,155
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL
Walczak, H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5386 · Cited by 1,130
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
Lowin, B., Hahne, M., Mattmann, C., & Tschopp, J. (1994) · Nature · doi:10.1038/370650a0 · Cited by 1,051
Self-citationBoldin, M. P., Varfolomeev, E. E., Pancer, Z., Mett, I. L., Camonis, J. H., & Wallach, D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.14.7795 · Cited by 993
Strand, S., Hofmann, W. J., Hug, H., Müller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., & Galle, P. R. (1996) · Nature Medicine · doi:10.1038/nm1296-1361 · Cited by 897
Metalloproteinase-mediated release of human Fas ligand.
Kayagaki, N., Kawasaki, A., Ebata, T., Ohmoto, H., Ikeda, S., Inoue, S., Yoshino, K., Okumura, K., & Yagita, H. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.6.1777 · Cited by 822
Degli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., & Goodwin, R. G. (1997) · Immunity · doi:10.1016/s1074-7613(00)80399-4 · Cited by 821
TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family That Weakly Induces Apoptosis
Chicheportiche, Y., Bourdon, P. R., Xu, H., Hsu, Y.-M., Scott, H., Hession, C., Garcia, I., & Browning, J. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.51.32401 · Cited by 694
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.
Galle, P. R., Hofmann, W. J., Walczak, H., Schaller, H., Otto, G., Stremmel, W., Krammer, P. H., & Runkel, L. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1223 · Cited by 692
Downregulation of Fas ligand by shedding
Tanaka, M., Itai, T., Adachi, M., & Nagata, S. (1998) · Nature Medicine · doi:10.1038/nm0198-031 · Cited by 669
Tanaka, M., Suda, T., Haze, K., Nakamura, N., Sato, K., Kimura, F., Motoyoshi, K., Mizuki, M., Tagawa, S., Ohga, S., et al. (1996) · Nature Medicine · doi:10.1038/nm0396-317 · Cited by 666
A novel receptor for Apo2L/TRAIL contains a truncated death domain
Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A. D., Godowski, P., et al. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00422-2 · Cited by 653
Expression of the functional soluble form of human fas ligand in activated lymphocytes.
Tanaka, M., Suda, T., Takahashi, T., & Nagata, S. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07096.x · Cited by 638
Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family
Degli-Esposti, M. A., Smolak, P. J., Walczak, H., Waugh, J., Huang, C.-P., DuBose, R. F., Goodwin, R. G., & Smith, C. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1165 · Cited by 629
Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing
Mohler, K. M., Sleath, P. R., Fitzner, J. N., Cerretti, D. P., Alderson, M., Kerwar, S. S., Torranee, D. S., Otten-Evans, C., Greenstreet, T., Weerawarna, K., et al. (1994) · Nature · doi:10.1038/370218a0 · Cited by 588
Lewis, M., Tartaglia, L. A., Lee, A., Bennett, G. L., Rice, G. C., Wong, G. H., Chen, E. Y., & Goeddel, D. V. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2830 · Cited by 567
Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor
McGeehan, G. M., Becherer, J. D., Bast, R. C., Boyer, C. M., Champion, B., Connolly, K. M., Conway, J. G., Furdon, P., Karp, S., Kidao, S., et al. (1994) · Nature · doi:10.1038/370558a0 · Cited by 561
French, L. E., Hahne, M., Viard, I., Radlgruber, G., Zanone, R., Becker, K., Müller, C., & Tschopp, J. (1996) · The Journal of cell biology · doi:10.1083/jcb.133.2.335 · Cited by 448
Self-citationMature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide.
Russell, J. H., Rush, B., Weaver, C., & Wang, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.10.4409 · Cited by 398
Braun, M. Y., Lowin, B., French, L., Acha-Orbea, H., & Tschopp, J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.2.657 · Cited by 297
Self-citationCharacterization of two receptors for TRAIL1
Schneider, P., Bodmer, J.-L., Thome, M., Hofmann, K., Holler, N., & Tschopp, J. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01231-3 · Cited by 290
Self-citationRegulation of cell surface APO‐1/Fas (CD95) ligand expression by metalloproteases
Mariani, S. M., Matiba, B., Bäumler, C., & Krammer, P. H. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250828 · Cited by 217
Characterization of Fas (Apo-1, CD95)-Fas Ligand Interaction
Schneider, P., Bodmer, J.-L., Holler, N., Mattmann, C., Scuderi, P., Terskikh, A., Peitsch, M. C., & Tschopp, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.30.18827 · Cited by 203
Self-citationRosendahl, M. S., Ko, S. C., Long, D. L., Brewer, M. T., Rosenzweig, B., Hedl, E., Anderson, L., Pyle, S. M., Moreland, J., Meyers, M. A., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24588 · Cited by 197
Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA
Marsters, S. A., Pitti, R. M., Donahue, C. J., Ruppert, S., Bauer, K. D., & Ashkenazi, A. (1996) · Current Biology · doi:10.1016/s0960-9822(09)00456-4 · Cited by 195
Local Fas/APO‐1 (CD95) ligand‐mediated tumor cell killing in vivo
Rensing‐Ehl, A., Frei, K., Flury, R., Matiba, B., Mariani, S. M., Weller, M., Aebischer, P., Krammer, P. H., & Fontana, A. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250821 · Cited by 191
Self-citationCharacterization of the non-functional Fas ligand of gld mice
Hahne, M., Peitsch, M. C., Irmler, M., Schröter, M., Lowln, B., Rousseau, M., Bron, C., Renno, T., French, L. E., & Tschopp, J. (1995) · International Immunology · doi:10.1093/intimm/7.9.1381 · Cited by 67
Self-citationThe relevance of apoptosis to AIDS pathogenesis
Ameisen, J. C., Estaquier, J., Idziorek, T., & BELS, F. D. (1995) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)88933-3 · Cited by 59
Cited by
Biological properties of extracellular vesicles and their physiological functions
Yáñez‐Mó, M., Siljander, P. R. ‐., Andreu, Z., Bedina Zavec, A., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27066 · Cited by 5,926
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., Bodmer, J.-L., Schneider, P., Seed, B., & Tschopp, J. (2000) · Nature Immunology · doi:10.1038/82732 · Cited by 1,938
Self-citationStrasser, A., O'Connor, L., & Dixit, V. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.217 · Cited by 1,351
BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth
Schneider, P., MacKay, F., Steiner, V., Hofmann, K., Bodmer, J.-L., Holler, N., Ambrose, C., Lawton, P., Bixler, S., Acha-Orbea, H., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.11.1747 · Cited by 1,333
Self-citation
Metadata
- Authors
- Schneider, P., Holler, N., Bodmer, J.-L., Hahne, M., Frei, K., Fontana, A., & Tschopp, J.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1998-04-20
- Volume
- 187
- Issue
- 8
- Pages
- 1205-1213
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W1975291295
- Cited by
- 812
- References
- 50
- FWCI
- 20.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.